Results 71 to 80 of about 72,405 (280)

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel

open access: yesRespiratory Medicine Case Reports, 2016
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction.
Ying Zhou   +3 more
doaj   +1 more source

Infliximab in ulcerative colitis

open access: yes, 2008
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to ...
Avi Levin, Oren Shibolet
core  

Switching from one infliximab biosimilar ({CT}-P13) to another infliximab biosimilar ({SB}2) in patients with chronic plaque psoriasis

open access: yes, 2020
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar ...
C. Virga   +6 more
core   +1 more source

Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index ...
Phoebe L. Sault   +3 more
wiley   +1 more source

Cystoid Macular Edema: Possible Complication of Infliximab Therapy in Behçet’s Disease

open access: yesCase Reports in Ophthalmology, 2010
Aim: Infliximab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, has been reported to be effective in refractory uveoretinitis in Behçet’s disease.
Junko Ikewaki   +4 more
doaj   +1 more source

Evaluation of the PK properties and biodistribution of pro-Infliximab and Infliximab.

open access: yes, 2019
The DBA/1J mice were intraperitoneally injected with 131I-labeled Infliximab (○) or 131I-labeled pro-Infliximab (□). The blood was collected at different time and the radioactivity was detected via the γ counter to measure the (A) PK properties of 131I ...
Kai-Wen Cheng (4583350)   +13 more
core   +1 more source

Infliximab in therapy of inflammatory bowels diseases [PDF]

open access: yes, 2019
Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim.
Rafał Filip   +9 more
core   +2 more sources

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

open access: yesGut and Liver
Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level.
Joo Hye Song   +7 more
doaj   +1 more source

Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy

open access: yesCase Reports in Gastroenterology, 2009
Tumor necrosis factor α plays an important role in the pathogenesis of Crohn’s disease (CD). The effects of infliximab on gastrointestinal bleeding in CD have not yet been fully evaluated.
Manzurul Chowdhury   +10 more
doaj   +1 more source

Dual biologic therapy in inflammatory bowel disease, a retrospective cohort study of vedolizumab and anti‐tumor necrosis factor alpha therapy in children

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy